MedTrace Logo

Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia

NCT02210962 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-02-18

No results posted yet for this study

Summary

There is accumulating experimental evidence to suggest the role of essential fatty acids (EFA) in neuronal migration, pruning and synaptic plasticity. These processes are implied to be dysfunctional on early stages of schizophrenia, according to neurodevelopmental hypothesis. Numerous epidemiological and clinical trial data support the benefit of EFA rich diets in reducing symptoms in schizophrenia. An EFA rich diet might be of particular importance at the beginning of the illness. As a relatively safe option, EFA supplementation would be a preferable add on therapy in treating individuals with a first episode of schizophrenia (FES) and a short duration of psychotic symptoms. No long term follow-up studies of EFA supplementation in FES patients were carried out. The demonstration of the efficacy of the prophylactic properties of EFAs in relapse prevention in FES patients would be a strong basis for further studies and prescribing EFAs for a large population of patients who are in the early stages of that debilitating illness.

Conditions

Interventions

DIETARY_SUPPLEMENT

essential fatty acids

Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)

DIETARY_SUPPLEMENT

olive oil

Yellow capsules containing olive oil (placebo)

Sponsors & Collaborators

  • Medical University of Lodz

    lead OTHER

Principal Investigators

  • Tomasz P Pawełczyk, MD, PhD · Department of Affective and Psychotic Disorders Medical University of Lodz

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02210962 on ClinicalTrials.gov